Many studies suggest that
catalase C-262T gene polymorphism is associated with
cancer risk, but with inconsistent results. This study aimed to summarize the overall association between
catalase C-262T polymorphism and
cancer risk. Literature search was performed in PubMed, Embase, and other databases, studies regarding the association between
catalase C-262T polymorphism and
cancer risk were identified, and data were retrieved and analyzed by using Review Manager 5.0.24 and STATA 12.0. A total of 18 publications with 22 case-control studies, including 9777
cancer patients and 12,223 controls, met the inclusion criteria. Meta-analysis results showed significant association between
catalase C-262 T polymorphism and
cancer risk (TT vs CT + CC: odds ratio [OR] = 1.17, 95% confidence interval [CI] = 1.03-1.31, P = 0.01). Subgroup analyses stratified by
cancer types suggested the
catalase C-262T polymorphism was significantly associated with an increased
prostate cancer risk (TT vs CT + CC: OR = 1.61, 95% CI = 1.17-2.22, P = 0.004); for subgroup analyses stratified by ethnicity, no associations between this polymorphism and Asians or whites were identified (CT + TT vs CC: OR = 1.11, 95% CI = 0.98-1.26, P = 0.09 for whites; OR = 1.19, 95% CI = 0.78-1.80, P = 0.42 for Asians). In summary, the
catalase C-262T polymorphism may be a risk factor for
cancer with
cancer type-specific effects. Further studies should be performed to confirm these findings.